Physician profile
Carlos E Buford
NPI 1568629970
$4,018.70
in general payments reported to CMS, 2019-2025
21 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.00 · 2023: $1,226 · 2024: $937 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,998.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $653.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $517.39 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abiomed | $368.58 | 2024-2025 | Impella |
| Amgen INC. | $344.27 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $322.47 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $268.76 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $265.48 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $188.88 | 2025 | Neffy |
| Idorsia Pharmaceuticals US INC | $136.98 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $124.98 | 2025 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $119.90 | 2024 | Dupixent |
| Axsome Therapeutics, INC. | $118.74 | 2025 | Auvelity |
| Genzyme Corporation | $118.71 | 2025 | |
| Viiv Healthcare Company | $118.63 | 2025 | |
| Gilead Sciences, INC. | $104.27 | 2023 | Descovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.70 | 2023-2025 | |
| Exact Sciences Corporation | $64.41 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.07 | 2023 | Xifaxan, Trulance |
| Edwards Lifesciences Corporation | $25.82 | 2025 | Sapien 3 Ultra Resilia |
| Antares Pharma, INC. | $17.97 | 2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $15.69 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Buford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.